←
Aya Helali MD PhD444 posts
Aya Helali MD PhD avatar✓

Aya Helali MD PhD ✓

@AyaHelali

Medical Oncologist, PhD, Clinician Scientist, Precision Oncology, Novice Crossfitter

◷ Joined May 2013▧ 38 Photos and videos
OncoAlert avatar
⟳ Aya Helali MD PhD retweeted
OncoAlert@OncoAlert·Oct 22

Precision oncology🎯 is evolving—but how do we distinguish a promising molecular target🧬 from one supported by evidence strong enough to guide treatment? sciencedirect.com/science/ar… The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology ESCAT v2 updates the ESMO framework for assessing molecular target actionability in precision oncology. ➡️ The revised classification refines evidence certainty within actionable tiers, introduces formal tumour-agnostic eligibility criteria through ETAC-S, and distinguishes non-predictive biomarkers from ineffective biomarker–therapy matches. ➡️ A complementary four-level resistance scale classifies evidence from clinically validated resistance to preclinical findings. ✅️ Together, these updates support more consistent interpretation of sensitivity and resistance biomarkers, helping guide therapeutic decisions and research priorities. @AyaHelali, @niamhjcoleman, @ekocakavuk, @clare__turnbull, @FerMosele, @CDebyaniPhD, @rdienstmann, @herbloong, @DMBranco, @quimmateo, @BenWestphalen

Post attachment
Annals of Oncology avatar
⟳ Aya Helali MD PhD retweeted
Annals of Oncology@Annals_Oncology·Oct 22

🆕 Article in press - The ESMO Scale for Clinical Actionability of molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology. 🔗tinyurl.com/4bdwu56h @AyaHelali

Post attachment
Aya Helali MD PhD avatar
Aya Helali MD PhD@AyaHelali·18 Oct 2025

🔬 Key findings: 1️⃣ #ecDNA supercharges oncogenes (EGFR/PDGFRA),creating aggressive tumor subtypes 2️⃣ Complex #EGFR ecDNA=worse survival (new prognostic marker?) 3️⃣ Epigenetic "lock" traps tumors in therapy-resistant states 4️⃣ Rewired immune microenvironment supports tumor growth

Herbert Loong, MBBS, FASCO avatar
⟳ Aya Helali MD PhD retweeted
Herbert Loong, MBBS, FASCO@herbloong·9 Jul 2025

Also had the opportunity to highlight our @CUHKMedicine @hkumed study that was published in @myESMO @ESMO_Open some years ago look at #comorbidities of patients w/ #sarcomas. We have identified that 10% of #newly diagnosed #sarcoma patients in #hongkong had #DiabetesMellitus, 5% w/ history of #CVA and 4% w/ #IHD. More co-morbidities associated with poorer prognosis and survival, independent of age. There maybe a role for #GPs and #primarycare colleagues to be more involved in #earlydetection and #identification of #atrisk individuals. @CarlosWongHKU

Post attachmentPost attachmentPost attachmentPost attachment